Story
Vaxcyte Shares Rise on Key Executive Hires, Updated VAX-31 Data Timeline
Shares of Vaxcyte Inc. (NASDAQ:PCVX) rose 6.3% in after-hours trading Thursday following an announcement that it has appointed two senior executives and provided a more specific timeline for pivotal data from its VAX-31 vaccine program.
Key Announcements
Vaxcyte, a clinical-stage vaccine developer, made two significant updates that captured investor attention. The company strengthened its leadership team with hires from major pharmaceutical firms and refined the schedule for a key clinical trial readout.
Leadership Appointments
The company named two new executives to its senior leadership team:
- Luis Jodar was appointed Chief Medical Officer. Mr. Jodar joins from Pfizer Inc., where he spent 17 years, most recently as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases. His experience includes work on major commercial programs such as Prevnar 13, Prevnar 20, and Comirnaty.
- David McAvoy was named Chief Legal Officer. Mr. McAvoy brings over 30 years of biopharmaceutical legal experience, previously serving as Executive Vice President and Chief Legal Officer at Teva Pharmaceutical Industries Ltd. and spending 27 years at Eli Lilly and Company.
Updated VAX-31 Timeline
AdVaxcyte also narrowed its guidance for the release of key clinical data. The company now expects to report topline safety, tolerability, and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial by the end of October 2026. This is a more precise timeline than its previous guidance of the fourth quarter of 2026.
Market Impact and Context
The dual announcements were received positively by the market, as the new hires from industry leaders like Pfizer and Teva can be seen as a vote of confidence in Vaxcyte's pipeline. Furthermore, reducing the uncertainty around the timing of a major data catalyst is typically viewed favorably by investors.
The VAX-31 adult Phase 3 program aims to support potential licensure for the prevention of invasive pneumococcal disease and pneumonia. The program's three clinical trials are fully enrolled, with a total of 6,191 adults dosed, according to the company.
Vaxcyte also stated it plans to announce data from the other two Phase 3 studies, OPUS-2 and OPUS-3, in the first half of 2027.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.